|
1
|
Boda D, Negrei C, Nicolescu F and Balalau
C: Assessment of some oxidative stress parameters in methotrexate
treated psoriasis patients. Farmacia. 62:704–710. 2014.
|
|
2
|
Căruntu C, Boda D, Căruntu A, Rotaru M,
Baderca F and Zurac S: In vivo imaging techniques for psoriatic
lesions. Rom J Morphol Embryol. 55 (Suppl):1191–1196.
2014.PubMed/NCBI
|
|
3
|
Batani A, Brănișteanu DE, Ilie MA, Boda D,
Ianosi S, Ianosi G and Caruntu C: Assessment of dermal papillary
and microvascular parameters in psoriasis vulgaris using in vivo
reflectance confocal microscopy. Exp Ther Med. 15:1241–1246.
2018.PubMed/NCBI
|
|
4
|
Nosotti L, Francesconi F, Izzi S,
Berardesca E, Morrone A and Bonifati C: Safety of antitumour
necrosis factor-α therapy in psoriatic patients with hepatitis B
virus infection. Br J Dermatol. 162:1408–1410. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fotiadou C, Lazaridou E and Ioannides D:
Safety of anti-tumour necrosis factor-α agents in psoriasis
patients who were chronic hepatitis B carriers: A retrospective
report of seven patients and brief review of the literature. J Eur
Acad Dermatol Venereol. 25:471–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cassano N, Mastrandrea V, Principi M,
Loconsole F, De Tullio N, Di Leo A and Vena GA: Anti-tumor necrosis
factor treatment in occult hepatitis B virus infection: A
retrospective analysis of 62 patients with psoriatic disease. J
Biol Regul Homeost Agents. 25:285–289. 2011.PubMed/NCBI
|
|
7
|
Prignano F, Ricceri F, Pescitelli L,
Zanieri F and Lotti T: Tumour necrosis factor-α antagonists in
patients with concurrent psoriasis and hepatitis B or hepatitis C:
A retrospective analysis of 17 patients. Br J Dermatol.
164:645–647. 2011.PubMed/NCBI
|
|
8
|
Romanian Therapeutic Guidelines: Chronic
Hepatitis. http://www.ms.ro/wp-content/uploads/2018/08/Anexa_Ordin_protocoale_29_august_2018.pdf
|
|
9
|
Zoulim F and Durantel D: Antiviral
therapies and prospects for a cure of chronic hepatitis B. Cold
Spring Harb Perspect Med. 5(a021501)2015.doi:
10.1101/cshperspect.a021501. PubMed/NCBI
|
|
10
|
Seto WK: Hepatitis B virus reactivation
during immunosuppressive therapy: Appropriate risk stratification.
World J Hepatol. 7:825–830. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Domm S, Cinatl J and Mrowietz U: The
impact of treatment with tumour necrosis factor-alpha antagonists
on the course of chronic viral infections: A review of the
literature. Br J Dermatol. 159:1217–1228. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Girolomoni G, Altomare G, Ayala F,
Berardesca E, Calzavara-Pinton P, Chimenti S, Peserico A, Puglisi
Guerra A and Vena GA: Safety of anti-TNFα agents in the treatment
of psoriasis and psoriatic arthritis. Immunopharmacol
Immunotoxicol. 34:548–560. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Olteanu R, Zota A and Constantin MM:
Biosimilars: An update on clinical trials (review of published and
ongoing studies). Acta Dermatovenerol Croat. 25:57–66.
2017.PubMed/NCBI
|
|
14
|
Sanz-Bueno J, Vanaclocha F, García-Doval
I, Torrado R, Carretero G, Daudén E, Patricia Ruiz-Genao D,
Alsina-Gibert MM, Pérez-Zafrilla B, Pérez-Rial G, et al members of
the BIOBADADERM group, : Risk of reactivation of hepatitis B virus
infection in psoriasis patients treated with biologics: A
retrospective analysis of 20 cases from the BIOBADADERM Database.
Actas Dermosifiliogr. 106:477–482. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee YH, Bae SC and Song GG: Hepatitis B
virus (HBV) reactivation in rheumatic patients with hepatitis core
antigen (HBV occult carriers) undergoing anti-tumor necrosis factor
therapy. Clin Exp Rheumatol. 31:118–121. 2013.PubMed/NCBI
|
|
16
|
Kuroda T, Wada Y, Kobayashi D, Sato H,
Murakami S, Nakano M and Narita I: Effect of etanercept and
entecavil in a patient with rheumatoid arthritis who is a hepatitis
B carrier: A review of the literature. Rheumatol Int. 32:1059–1063.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chung SJ, Kim JK, Park MC, Park YB and Lee
SK: Reactivation of hepatitis B viral infection in inactive HBsAg
carriers following anti-tumor necrosis factor-alpha therapy. J
Rheumatol. 36:2416–2420. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Strohal R, Chimenti S, Vena GA and
Girolomoni G: Etanercept provides an effective, safe and flexible
short- and long-term treatment regimen for moderate-to-severe
psoriasis: A systematic review of current evidence. J Dermatolog
Treat. 24:199–208. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strohal R, Puig L, Chouela E, Tsai TF,
Melin J, Freundlich B, Molta CT, Fuiman J, Pedersen R and Robertson
D: The efficacy and safety of etanercept when used with as-needed
adjunctive topical therapy in a randomised, double-blind study in
subjects with moderate-to-severe psoriasis (the PRISTINE trial). J
Dermatolog Treat. 24:169–178. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Esposito M, Gisondi P, Cassano N, Babino
G, Cannizzaro MV, Ferrucci G, Chimenti S and Giunta A: Treatment
adherence to different etanercept regimens, continuous vs.
intermittent, in patients affected by plaque-type psoriasis. Drug
Dev Res. 75 (Suppl 1):S31–S34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Babino G, Esposito M, Mazzotta A, Chimenti
S and Giunta A: Entecavir and intermittent etanercept therapy in a
patient with concurrent hepatitis B virus infection and psoriasis.
Acta Derm Venereol. 93:373–374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Olteanu R, Constantin MM, Zota A,
Dorobantu DM, Constantin T, Șerban ED, Bălănescu P, Mihele D and
Gheucă Solovăstru L: Original clinical experience and approach to
treatment study with interleukin 12/23 inhibitor in
moderate-to-severe psoriasis patients. Farmacia. 64:918–921.
2016.
|
|
23
|
Căruntu C, Boda D, Musat S, Căruntu A and
Mandache E: Stress-induced mast cell activation in glabrous and
hairy skin. Mediators Inflamm. 2014:1059502014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Negrei C, Arsene AL, Toderescu CD, Boda D
and Ilie M: Acitretin treatment in psoriasis may influence the cell
membrane fluidity. Farmacia. 60:767–771. 2012.
|
|
25
|
Caruntu C, Boda D, Dumitrascu G,
Constantin C and Neagu M: Proteomics focusing on immune markers in
psoriatic arthritis. Biomarkers Med. 9:513–528. 2015. View Article : Google Scholar
|
|
26
|
Motaparthi K, Stanisic V, Van Voorhees AS,
Lebwohl MG and Hsu S; Medical Board of the National Psoriasis
Foundation, : From the Medical Board of the National Psoriasis
Foundation: Recommendations for screening for hepatitis B infection
prior to initiating anti-tumor necrosis factor-alfa inhibitors or
other immunosuppressive agents in patients with psoriasis. J Am
Acad Dermatol. 70:178–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
